Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sage Therapeutics Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active case is assigned to 1 distinct examiner, indicating a focused point of contact at the patent office. The prosecution is localized in 1 distinct art unit, which suggests a specific technical focus for the company's current intellectual property strategy.
RAO, PADMAJA S is identified as the busiest examiner for the portfolio, currently managing 1 pending office action. This count of 1 is equal to the total number of pending office actions, meaning the entire active portfolio is under the review of this single examiner. For the applicant, this means that the outcome of current filings is tied to the specific tendencies of this individual. Practitioners must focus on the particular examination style of this examiner and the standards of the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613870 | CYP46A1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | RAO, PADMAJA S | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17613870 | CYP46A1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | RAO, PADMAJA S | 1627 | Other | Non-Final OA | — | Pending | Nov 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial